Published in Nat Med on March 01, 2004
GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One (2007) 1.99
Protection of visual functions by human neural progenitors in a rat model of retinal disease. PLoS One (2007) 1.38
Neuron-like differentiation of bone marrow-derived mesenchymal stem cells. Yonsei Med J (2011) 1.13
Chromosome 7 and 19 trisomy in cultured human neural progenitor cells. PLoS One (2009) 1.13
Lesion-induced increase in survival and migration of human neural progenitor cells releasing GDNF. Cell Transplant (2008) 1.05
Stem cell transplantation for motor neuron disease: current approaches and future perspectives. Neurotherapeutics (2011) 0.92
Differentiation of CD133+ stem cells from amyotrophic lateral sclerosis patients into preneuron cells. Stem Cells Transl Med (2013) 0.78
Isolation of human foetal myoblasts and its application for microencapsulation. J Cell Mol Med (2008) 0.77
Regionally-specified second trimester fetal neural stem cells reveals differential neurogenic programming. PLoS One (2014) 0.76
Safety profile of bone marrow mononuclear stem cells in the rehabilitation of patients with posttraumatic facial nerve paralysis-a novel modality (phase one trial). J Neurol Surg B Skull Base (2012) 0.76
Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet (2011) 5.01
Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect (2011) 3.87
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 3.37
Solvent exposures and Parkinson disease risk in twins. Ann Neurol (2011) 2.92
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis (2002) 2.83
Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol (2008) 2.04
Head injury and Parkinson's disease risk in twins. Ann Neurol (2006) 1.93
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology (2009) 1.63
Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol (2009) 1.56
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS One (2011) 1.37
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol (2007) 1.25
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol (2002) 1.22
Crossroads in GDNF therapy for Parkinson's disease. Mov Disord (2006) 1.19
Head injury, α-synuclein Rep1, and Parkinson's disease. Ann Neurol (2012) 1.14
Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol Dis (2007) 1.11
Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother (2009) 1.08
Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem (2006) 1.06
Voluntarily simulated tremor in normal subjects. Neurophysiol Clin (2002) 1.03
Can cellular models revolutionize drug discovery in Parkinson's disease? Biochim Biophys Acta (2009) 1.03
Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. J Neurosci (2006) 1.00
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease. Toxicol Lett (2011) 0.99
Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment. J Neurochem (2006) 0.99
Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. Parkinsonism Relat Disord (2012) 0.98
Mitochondrial dysfunction in skin fibroblasts from a Parkinson's disease patient with an alpha-synuclein triplication. J Parkinsons Dis (2011) 0.98
The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci Methods (2005) 0.96
Small molecules greatly improve conversion of human-induced pluripotent stem cells to the neuronal lineage. Stem Cells Int (2012) 0.95
Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol (2006) 0.95
Genetic modification of the association of paraquat and Parkinson's disease. Mov Disord (2012) 0.91
Model fusion, the next phase in developing animal models for Parkinson's disease. Neurotox Res (2007) 0.90
Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Mov Disord (2011) 0.89
Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. PLoS One (2013) 0.88
α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis (2012) 0.88
Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther (2004) 0.87
Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J Neurochem (2002) 0.87
Decreased alpha-synuclein expression in the aging mouse substantia nigra. Exp Neurol (2009) 0.87
Smell identification ability in twin pairs discordant for Parkinson's disease. Mov Disord (2005) 0.86
The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys. Mov Disord (2002) 0.85
Relationship of neighboring tissue and gliosis to α-synuclein pathology in a fetal transplant for Parkinson's disease. Am J Neurodegener Dis (2012) 0.83
Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine. J Pharmacol Exp Ther (2006) 0.83
The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Exp Neurol (2007) 0.81
Parkin gene variations and parkinsonism: association does not imply causation. Ann Neurol (2007) 0.80
Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation. Mov Disord (2003) 0.79
The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. J Neurosurg (2009) 0.79
GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol (2006) 0.78
How many pathways are there to nigral death? Ann Neurol (2004) 0.78
Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage. J Mol Neurosci (2009) 0.77
Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. Exp Neurol (2003) 0.77
Screening of ferritin light polypeptide 460-461InsA mutation in Parkinson's disease patients in North America. Neurosci Lett (2002) 0.76
Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord (2014) 0.76
Ubiquitin-positive neuronal and tau 2-positive glial inclusions in frontotemporal dementia of motor neuron type. Acta Neuropathol (2002) 0.76
The MPTP Story. J Parkinsons Dis (2017) 0.75
Erratum: Multisystem Lewy body disease and the other parkinsonian disorders. Nat Genet (2016) 0.75
Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology (2005) 0.75
Journal of Parkinson's Disease--an excellent first year and a new sister. J Parkinsons Dis (2012) 0.75
Journal of Parkinson's disease. J Parkinsons Dis (2011) 0.75
Imaging and therapeutics: the role of neuronal transport in the regional specificity of L-DOPA accumulation in brain. Mol Imaging Biol (2002) 0.75